Eyetelligence Becomes Optain Mivision Eyetelligence has announced a significant milestone, officially changing its name to optain. in a media release, the company said the strategic decision reflects the alignment and integration of eyetelligence with its parent company, optain health. Learn about optain health, pioneers in ai enabled retinal imaging. discover our mission to improve global health outcomes. explore more today.
Eyetelligence Changes Name To Optain Eyetelligence will continue to expand both in australia and in other international markets. as the brand grows and scales, the ascertain team is determined to foster innovation and improve patient care by investing in and cultivating solutions like those offered by optain. Optain’s technology expands access to oculomics into primary care, optometry, and beyond, with minimal specialist staffing or workflow disruption. “our mission is simple: faster, easier, more equitable disease screening,” said jeff dunkel, ceo, optain. This strategic decision aligns eyetelligence with its parent company, optain health, following substantial investments that solidify the company's commitment to excellence and innovation. Eyetelligence will be rebranded and launched in the us as optain, offering non invasive point of care technology to diagnose a range of diseases more rapidly and cost effectively.
Eyetelligence Assure Ai Retinal Screening Tool Optain Health This strategic decision aligns eyetelligence with its parent company, optain health, following substantial investments that solidify the company's commitment to excellence and innovation. Eyetelligence will be rebranded and launched in the us as optain, offering non invasive point of care technology to diagnose a range of diseases more rapidly and cost effectively. Eyetelligence will be rebranded and launched in the us as optain and aims to enable non invasive point of care technology to diagnose a range of diseases more rapidly, cost effectively, and accessibly. "we are excited about this change, which represents a strategic alignment with our parent company's vision and values," said rainer grote, senior vice president at optain. Optain health has closed a $26 million series a funding round to accelerate the deployment of its ai powered retinal screening technology across the united states. With this $12 million investment, optain is the first company launched by ascertain, aegis ventures and northwell holdings' collaboration to develop healthcare ai companies at scale.
Comments are closed.